Strategic Blueprint LLC Sells 1,310 Shares of Eli Lilly and Company $LLY

Strategic Blueprint LLC cut its holdings in Eli Lilly and Company (NYSE:LLY) by 8.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 14,225 shares of the company’s stock after selling 1,310 shares during the quarter. Strategic Blueprint LLC’s holdings in Eli Lilly and Company were worth $10,854,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Sumitomo Mitsui Financial Group Inc. acquired a new position in shares of Eli Lilly and Company during the second quarter worth approximately $27,000. Evolution Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company in the second quarter valued at approximately $29,000. Steph & Co. increased its holdings in shares of Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after purchasing an additional 29 shares in the last quarter. Financial Gravity Companies Inc. acquired a new position in Eli Lilly and Company during the 2nd quarter worth $31,000. Finally, Bare Financial Services Inc lifted its holdings in Eli Lilly and Company by 263.6% during the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after buying an additional 29 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY opened at $1,086.28 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The stock has a market cap of $1.03 trillion, a P/E ratio of 53.14, a price-to-earnings-growth ratio of 0.80 and a beta of 0.35. The stock’s 50-day moving average price is $1,033.14 and its two-hundred day moving average price is $858.57.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.Eli Lilly and Company’s revenue was up 53.9% on a year-over-year basis. During the same period in the prior year, the business posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Late‑stage data: Lilly reported a trial where its weight‑loss drug Zepbound plus Taltz improved psoriatic‑arthritis symptoms and produced additional weight loss versus Taltz alone — a clinical win that could expand commercial use and bolster Zepbound’s franchise. Lilly’s Zepbound plus Taltz boosts arthritis relief, weight loss in late-stage trial
• Positive Sentiment: Distribution/DTC reach: Walmart’s new Better Care Services includes LillyDirect as a partner, increasing direct‑to‑consumer visibility and distribution options for Lilly’s digital/patient offerings. Walmart Launches Digital Destination Focused on Health and Wellness
• Positive Sentiment: M&A / diversification: Lilly agreed to buy Ventyx Biosciences for roughly $1.2B to add oral anti‑inflammatory (NLRP3) candidates — a strategic move to diversify beyond GLP‑1 obesity/diabetes products. Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal
• Neutral Sentiment: Analyst/market context: Some firms (e.g., Citigroup, Zacks) still highlight outsized upside for LLY and include it on buy lists, supporting longer‑term bullish views despite short‑term volatility. Eli Lilly Stock (LLY) Has 50% Upside, Says Citigroup
• Negative Sentiment: Legal/regulatory risk: The Indiana attorney general sued Lilly over insulin pricing, a reminder of political and litigation risks around affordability that could pressure sentiment and margins. Indiana attorney general sues Eli Lilly over insulin pricing
• Negative Sentiment: Deal uncertainty: A shareholder investigation into Ventyx’s board over the sale price (and analyst caution about NLRP3 pathway uncertainty) could create noise or drag around the acquisition’s execution and perceived value. SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX)
• Negative Sentiment: Profit‑taking / market rotation: LLY recently hit all‑time highs and led healthcare rallies; today’s pullback looks partly like investors trimming positions and rotating within the sector. Eli Lilly stock hits all-time high

Analyst Upgrades and Downgrades

Several research firms have recently commented on LLY. Guggenheim reissued a “buy” rating and issued a $1,163.00 target price on shares of Eli Lilly and Company in a research note on Wednesday, December 3rd. Daiwa Capital Markets set a $1,230.00 price target on Eli Lilly and Company and gave the company a “buy” rating in a report on Tuesday, December 16th. Loop Capital set a $950.00 price objective on Eli Lilly and Company in a report on Monday, November 10th. CICC Research upped their target price on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a research report on Thursday, November 13th. Finally, Leerink Partners set a $1,234.00 price target on shares of Eli Lilly and Company in a research report on Monday. Five equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Buy” and an average target price of $1,169.00.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.